Creative Medical Technology Holdings, Inc.
Moat Score — Creative Medical Technology Holdings, Inc.
Total Moat Score
2 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | The company holds a broad portfolio of patented perinatal-derived cell therapy platforms (CaverStem, FemCelz, CELZ-201, Ultrasome, ImmCelz, MyeloCelz), a real but largely pre-commercial and unproven IP base. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | With only about 4 employees and $6,000 of annual revenue, Creative Medical has no scale or cost advantage of any kind. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Revenue is negligible and declining, showing essentially no demonstrated pricing power or market demand at current scale. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Regenerative cell therapy procedures and products carry no network effect between patients or providers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | As largely elective, one-time procedures or early clinical-trial therapies, there is no meaningful switching cost locking patients or physicians into Creative Medical's offerings over alternatives. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The regenerative medicine space includes far larger, better-funded competitors, and Creative Medical's minimal scale provides no efficient-scale protection. |